Literature DB >> 34003059

Digital Mammography and Breast Tomosynthesis Performance in Women with a Personal History of Breast Cancer, 2007-2016.

Janie M Lee1, Laura E Ichikawa1, Karen J Wernli1, Erin Bowles1, Jennifer M Specht1, Karla Kerlikowske1, Diana L Miglioretti1, Kathryn P Lowry1, Anna N A Tosteson1, Natasha K Stout1, Nehmat Houssami1, Tracy Onega1, Diana S M Buist1.   

Abstract

Background Since 2007, digital mammography and digital breast tomosynthesis (DBT) replaced screen-film mammography. Whether these technologic advances have improved diagnostic performance has, to the knowledge of the authors, not yet been established. Purpose To evaluate the performance and outcomes of surveillance mammography (digital mammography and DBT) performed from 2007 to 2016 in women with a personal history of breast cancer and compare with data from 1996 to 2007 and the performance of digital mammography screening benchmarks. Materials and Methods In this observational cohort study, five Breast Cancer Surveillance Consortium registries provided prospectively collected mammography data linked with tumor registry and pathologic outcomes. This study identified asymptomatic women with American Joint Committee on Cancer anatomic stages 0-III primary breast cancer who underwent surveillance mammography from 2007 to 2016. The primary outcome was a second breast cancer diagnosis within 1 year of mammography. Performance measures included the recall rate, cancer detection rate, interval cancer rate, positive predictive value of biopsy recommendation, sensitivity, and specificity. Results Among 32 331 women who underwent 117 971 surveillance mammographic examinations (112 269 digital mammographic examinations and 5702 DBT examinations), the mean age at initial diagnosis was 59 years ± 12 (standard deviation). Of 1418 second breast cancers diagnosed, 998 were surveillance-detected cancers and 420 were interval cancers. The recall rate was 8.8% (10 365 of 117 971; 95% CI: 8.6%, 9.0%), the cancer detection rate was 8.5 per 1000 examinations (998 of 117 971; 95% CI: 8.0, 9.0), the interval cancer rate was 3.6 per 1000 examinations (420 of 117 971; 95% CI: 3.2, 3.9), the positive predictive value of biopsy recommendation was 31.0% (998 of 3220; 95% CI: 29.4%, 32.7%), the sensitivity was 70.4% (998 of 1418; 95% CI: 67.9%, 72.7%), and the specificity was 98.1% (114 331 of 116 553; 95% CI: 98.0%, 98.2%). Compared with previously published studies, interval cancer rate was comparable with rates from 1996 to 2007 in women with a personal history of breast cancer and was higher than the published digital mammography screening benchmarks. Conclusion In transitioning from screen-film to digital mammography and digital breast tomosynthesis, surveillance mammography performance demonstrated minimal improvement over time and remained inferior to the performance of screening mammography benchmarks. © RSNA, 2021 Online supplemental material is available for this article. See also the editorial by Moy and Gao in this issue.

Entities:  

Mesh:

Year:  2021        PMID: 34003059      PMCID: PMC8328154          DOI: 10.1148/radiol.2021204581

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   29.146


  30 in total

1.  Five-year risk of interval-invasive second breast cancer.

Authors:  Janie M Lee; Diana S M Buist; Nehmat Houssami; Emily C Dowling; Elkan F Halpern; G Scott Gazelle; Constance D Lehman; Louise M Henderson; Rebecca A Hubbard
Journal:  J Natl Cancer Inst       Date:  2015-04-22       Impact factor: 13.506

2.  Overutilization of Health Care Resources for Breast Pain.

Authors:  Anne C Kushwaha; Kyungmin Shin; Megan Kalambo; Ravinder Legha; Karen E Gerlach; Megha Madhukar Kapoor; Wei T Yang
Journal:  AJR Am J Roentgenol       Date:  2018-05-24       Impact factor: 3.959

Review 3.  Imaging Surveillance After Primary Breast Cancer Treatment.

Authors:  Diana L Lam; Nehmat Houssami; Janie M Lee
Journal:  AJR Am J Roentgenol       Date:  2017-01-11       Impact factor: 3.959

4.  Imaging Surveillance of Breast Cancer Survivors with Digital Mammography versus Digital Breast Tomosynthesis.

Authors:  Manisha Bahl; Sarah Mercaldo; Anne Marie McCarthy; Constance D Lehman
Journal:  Radiology       Date:  2020-12-22       Impact factor: 11.105

5.  Diagnosis of second breast cancer events after initial diagnosis of early stage breast cancer.

Authors:  Diana S M Buist; Linn A Abraham; William E Barlow; Arun Krishnaraj; Regan C Holdridge; Edward A Sickles; Patricia A Carney; Karla Kerlikowske; Berta M Geller
Journal:  Breast Cancer Res Treat       Date:  2010-08-11       Impact factor: 4.872

6.  Tumor characteristics associated with mammographic detection of breast cancer in the Ontario breast screening program.

Authors:  Victoria A Kirsh; Anna M Chiarelli; Sarah A Edwards; Frances P O'Malley; Rene S Shumak; Martin J Yaffe; Norman F Boyd
Journal:  J Natl Cancer Inst       Date:  2011-05-03       Impact factor: 13.506

7.  National Performance Benchmarks for Modern Screening Digital Mammography: Update from the Breast Cancer Surveillance Consortium.

Authors:  Constance D Lehman; Robert F Arao; Brian L Sprague; Janie M Lee; Diana S M Buist; Karla Kerlikowske; Louise M Henderson; Tracy Onega; Anna N A Tosteson; Garth H Rauscher; Diana L Miglioretti
Journal:  Radiology       Date:  2016-12-05       Impact factor: 11.105

8.  Supplemental Breast US Screening in Women with a Personal History of Breast Cancer: A Matched Cohort Study.

Authors:  Soo-Yeon Kim; Nariya Cho; Soo Yeon Kim; Yunhee Choi; Eun Sil Kim; Su Min Ha; Su Hyun Lee; Jung Min Chang; Woo Kyung Moon
Journal:  Radiology       Date:  2020-02-25       Impact factor: 11.105

9.  Breast Cancer Screening in Women at Higher-Than-Average Risk: Recommendations From the ACR.

Authors:  Debra L Monticciolo; Mary S Newell; Linda Moy; Bethany Niell; Barbara Monsees; Edward A Sickles
Journal:  J Am Coll Radiol       Date:  2018-01-19       Impact factor: 5.532

10.  Biological characteristics of interval cancers: a role for biomarkers in the breast cancer screening.

Authors:  A Caldarella; D Puliti; E Crocetti; S Bianchi; V Vezzosi; P Apicella; M Biancalani; A Giannini; C Urso; F Zolfanelli; E Paci
Journal:  J Cancer Res Clin Oncol       Date:  2012-09-09       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.